Table 1.
Summary of 25(OH)D levels before and after supplementation in trials published during the Period 2015–2017,a with at least 50 participants per arm.
| Author year/country | Dose | Mean age (years) | Gender (% female) | Duration | Baseline 25(OH)D (ng/ml) | Achieved 25(OH)D (ng/ml) | Δ 25(OH)D (ng/ml) | Δ 25(OH)D/100 IU/d (ng/ml) | 25(OH)D level assay |
|---|---|---|---|---|---|---|---|---|---|
| Infants and children | |||||||||
|
Saad et al., 2018 Egypt |
300 IU/kg/d | 5 | 22 | 4 mo | 26 | 46 | 20 | NA | ELISA |
| PBO | 6 | 27 | 28 | 1 | |||||
|
Talaat et al., 2016 KSA |
400 | 8 | 51 | 12 mo | 22 | 10 | −12 | NA | CLIA |
| 45,000 IU/w (2 mo) than 400 IU/d | 9 | 14 | 23 | 9 | |||||
| 2000 IU/d (3 mo) then 1000 IU/d | 8 | 13 | 38 | 25 | |||||
| Pregnant women | |||||||||
|
Mojibian et al., 2015 Iran |
400 IU/d | 27 | 100 | 12 w GA till delivery | 15 | 27 | 12 | 3 | ELISA |
| 50,000 IU/2 w (3570 IU/d) | 28 | 15 | 38 | 23 | 0.6 | ||||
|
Vaziri et al., 2016 Iran |
2000 | 32 | 100 | 26–28 w GA until delivery | 12 | 18 | 6 | 0.3 | CLIA |
| PBO | 26 | 13 | 12 | −1 | NA | ||||
| Adults | |||||||||
|
Taheri et al., 2015 Iran |
2000 | 30 | 100 | 3.7 mo | 9 | 28 | 19 | 0.9 | EIA |
| C | 29 | 9 | 9 | 0 | NA | ||||
|
El-Hajj Fuleihan et al., 2016 Lebanon |
600 | 71 | 57 | 12 mo | 20 | 26 | 6 | 0.9 | LCMS |
| 3750 | 71 | 54 | 21 | 36 | 15 | 0.4 | |||
|
Tepper et al., 2016 Occupied Palestine-Israel |
100,000 IU bimonthly (6666 IU/d) | 48 | 0 | 12 mo | 16 | 26 | 10 | 0.1 | NR |
| PBO | 15 | 21 | 6 | NA | |||||
|
Zarrin et al., 2017b Iran |
1000 | 48 | 53 | 3 mo | 19 | – | 11 | 1.1 | ELISA |
| PBO | 48 | 51 | 15 | – | −2 | NA | |||
|
Kamelian et al., 2017b Iran |
7142 | 39 | 69 | 9 mo | 8 | – | 32 | 0.4 | CLIA |
| PBO | 41 | 63 | 8 | – | 9 | NA | |||
Abbreviations: C: control; CLIA: Chemiluminescence Immunoassay; EIA: Enzymatic Immune Assay; ELISA: Enzyme Linked Immunosorbent Assay; GA: gestational age; LCMS: Liquid Chromatography Mass; mo: months; Spectrometry; NA: not applicable; NR: not reported; PBO: Placebo; w: weeks.
a
This is an update of a previous systematic review on vitamin D randomized controlled trials conducted in the MENA region. For further details, refer to the main text and to previous publications (Chakhtoura et al., 2017a, Chakhtoura et al., 2017b).
b
Achieved 25(OH)D level not reported but the change in 25(OH)D level reported.